Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone

被引:98
作者
Cormican, MG [1 ]
Jones, RN [1 ]
机构
[1] UNIV IOWA,COLL MED,DEPT PATHOL,DIV MED MICROBIOL,IOWA CITY,IA 52242
关键词
D O I
10.1128/AAC.41.1.204
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Compound LB20304 is a fluoronaphthyridone carboxylic acid with a novel pyrrolidine substituent. This drug was compared with ciprofloxacin, levofloxacin, ofloxacin, sparfloxacin, and trovafloxacin against over 800 pathogens, most from blood stream infections, by National Committee for Clinical Laboratory Standards reference methods, LB20304 was the most active agent against gram-positive species including strains observed to be resistant to other fluoroquinolones and glycopeptides. The potency of LB20304 (MIC(50), 0.03 mu g/ml) against the Enterobacteriaceae was exceeded only by that of ciprofloxacin (0.015 mu g/ml). It has limited activity against gram-negative anaerobes.
引用
收藏
页码:204 / 211
页数:8
相关论文
共 12 条
  • [1] GOOTZ TD, 1994, DIAGN MICR INFEC DIS, V19, P235
  • [2] THE IN-VITRO ACTIVITY OF A NEW HIGHLY-ACTIVE QUINOLONE, DU-6859A
    JOLLEY, A
    ANDREWS, JM
    BRENWALD, N
    WISE, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (05) : 757 - 763
  • [3] PREVALENCE OF IMPORTANT PATHOGENS AND ANTIMICROBIAL ACTIVITY OF PARENTERAL DRUGS AT NUMEROUS MEDICAL-CENTERS IN THE UNITED-STATES .1. STUDY ON THE THREAT OF EMERGING RESISTANCES - REAL OR PERCEIVED
    JONES, RN
    KEHRBERG, EN
    ERWIN, ME
    ANDERSON, SC
    BEAVIS, K
    BERMAN, M
    BOURBEAU, P
    SINNOTT, J
    CANAWATI, H
    CAVALIERI, S
    COCKERILL, F
    DELLALATTA, P
    DENYS, G
    DOERN, G
    FORBES, B
    GAMBLE, S
    GOODMAN, N
    HAUGEN, T
    HINDLER, J
    HUMPHRIES, J
    JOSEPHSON, S
    KAUFFMAN, C
    LIBERTINE, C
    MAUNEY, C
    METCHOCK, B
    MICHELSON, P
    MURRAY, P
    NEEDHAM, C
    OELSCHDAEGER, R
    PRICE, M
    SACEANU, C
    SCHWALBE, R
    SEGRETI, J
    SEWELL, D
    SIERRA, M
    SLIFKIN, M
    SNYDMAN, D
    SOUTHERN, P
    SPIEGEL, C
    STEELEMOORE, L
    STEIN, G
    STRATTON, C
    WANGER, A
    WASHINGTON, J
    WASILAUSKAS, B
    WEINSTEIN, M
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1994, 19 (04) : 203 - 215
  • [4] KIM SI, 1995, J APPL PHARM, V3, P322
  • [5] KIM YK, 1995, 35 INT C ANT AG CHEM, P148
  • [6] PNEUMOCOCCAL RESISTANCE TO ANTIBIOTICS
    KLUGMAN, KP
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 1990, 3 (02) : 171 - 196
  • [7] *NAT COMM CLIN LAB, 1995, M100S6 NAT COMM CLIN
  • [8] National Committee for Clinical Laboratory Standards, 1993, M7A3 NAT COMM CLIN L
  • [9] NEU HC, 1989, ANTIMICROB AGENTS CH, V22, P548
  • [10] In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone
    Oh, JI
    Paek, KS
    Ahn, MJ
    Kim, MY
    Hong, CY
    Kim, IC
    Kwak, JH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) : 1564 - 1568